60 research outputs found
Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data
Nonalcoholic fatty liver disease (NAFLD) is the most common, chronic liver disease worldwide. Within this spectrum, steatosis alone is apparently benign, while nonalcoholic steatohepatitis may progress to cirrhosis and hepatocellular carcinoma. NAFLD is strongly associated with obesity, dyslipidemia, type 2 diabetes mellitus, and cardiovascular disease. The pathogenesis of hepatic steatosis is not clearly known, but its main characteristics are considered insulin resistance, mitochondrial dysfunction, increased free fatty acids reflux from adipose tissue to the liver, hepatocyte lipotoxicity, stimulation of chronic necroinflammation, and fibrogenic response. With recent advances in technology, advanced imaging techniques provide important information for diagnosis. There is a significant research effort in developing noninvasive monitoring of disease progression to fibrosis and response to therapy with potential novel biomarkers, in order to facilitate diagnosis for the detection of advanced cirrhosis and to minimize the need of liver biopsy. The identification of NAFLD should be sought as part of the routine assessment of type 2 diabetics, as sought the microvascular complications and cardiovascular disease, because it is essential for the early diagnosis and proper intervention. Diet, exercise training, and weight loss provide significant clinical benefits and must be considered of first line for treating NAFLD
Is Neuregulin‐4 a predictive marker of microvascular complications in type 2 diabetes mellitus?
Fibrinogen and Albuminuria are Related to the Presence and Severity of Peripheral Arterial Disease in Women with Type 2 Diabetes Mellitus
Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy
Women with polycystic ovary syndrome who present with hyperandrogenemia,
hyperinsulinemia, and insulin resistance appear to be at high risk of
cardiovascular disease. Elevated levels of endothelin-1, a marker of
vasculopathy, have been reported in insulin-resistant subjects with
endothelial dysfunction. Male gender also seems to be an aggravating
factor for cardiovascular disease.
In this study we investigated endothelin-1 levels in women with
polycystic ovary syndrome, and we evaluated the effect of an insulin
sensitizer, metformin, on endothelin-1 levels. Plasma endothelin-1
levels were measured in 23 obese (mean age, 24.3 +/- 4.6 yr; body mass
index, 35 +/- 5.6 kg/m(2)) and 20 nonobese women with polycystic ovary
syndrome (24.1 +/- 3.6 yr; body mass index, 21.8 +/- 2.5 kg/m(2)) as
well as in 7 obese and 10 nonobese healthy, normal cycling, age-matched
women. Additionally, endothelin-1 levels were evaluated in a subgroup of
women with polycystic ovary syndrome (10 obese and 10 nonobese) 6 months
postmetformin administration (1700 mg daily).
Our results showed that obese and nonobese women with polycystic ovary
syndrome had higher levels of endothelin-1 compared with the controls
[obese, 2.52 +/- 1.87 vs. 0.44 +/- 0.23 pmol/liter (by analysis of
covariance, P < 0.02); nonobese, 1.95 +/- 1.6 vs. 0.43 +/- 0.65
pmol/liter (P < 0.009)]. All of the participating women with polycystic
ovary syndrome (n = 43) when compared with the total group of controls
(n = 17) demonstrated hyperinsulinemia (polycystic ovary syndrome, 24.5
+/- 19.6; controls, 11.2 +/- 3.4 U/liter; P < 0.03), lower glucose
utilization (M40) during the hyperinsulinemic euglycemic clamps (3.4 +/-
2.4 vs. 5.6 +/- 1.75 mg/kg.min; P < 0.045, by one-tailed test), and
higher levels of endothelin-1 (polycystic ovary syndrome, 2.52 +/- 1.87;
controls, 0.44 +/- 0.23 pmol/liter; P < 0.02, analysis of covariance
covariate for body mass index). A positive correlation of endothelin-1
with free T levels was also shown (r = 0.4, P = 0.002) as well as a
negative correlation of endothelin-1 with glucose utilization (r = -0.3;
P = 0.033) in the total studied population.
Finally, after metformin therapy, endothelin-1 levels were significantly
reduced in obese (endothelin-1 before, 3.25 +/- 2.2; endothelin-1 after,
1.1 +/- 0.9 pmol/liter; P < 0.003) and nonobese (endothelin-1 before,
2.7 +/- 2; endothelin-1 after, 0.7 +/- 0.4 pmol/liter; P < 0.01) women
with polycystic ovary syndrome, with no change in body mass index.
Moreover, after metformin therapy, hyperandrogenemia and
hyperinsulinemia were normalized, and glucose utilization improved
[obese before: total T, 0.9 +/- 0.15 ng/ml; fasting insulin, 22.2 +/-
12.1 U/liter; glucose utilization, 2.15 +/- 0.5 mg/kg.min; obese after:
total T, 0.5 +/- 0.2 ng/ml; fasting insulin, 11.6 +/- 6 U/liter; glucose
utilization, 4.7 +/- 1.4 mg/kg.min 9P < 0.003, P < 0.006, and P < 0.002,
respectively); nonobese before: total T, I 0.5 ng/ml; fasting insulin,
15.5 +/- 7.6 U/liter; glucose utilization, 3.4 +/- 0.7 mg/kg.min;
nonobese after: total T, 0.8 +/- 0.5 ng/ml; fasting insulin, 9 +/- 3.8
U/liter; glucose utilization, 6 +/- 1.7 mg/kg.min (P < 0.04, P < 0.02,
and P < 0.0008, respectively)].
In conclusion, our data clearly demonstrate that women with polycystic
ovary syndrome, obese and nonobese, have elevated endothelin-1 levels
compared with the age-matched control group. In addition, 6 months of
metformin therapy reduces endothelin-1 levels and improves their
hormonal and metabolic profile
Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy
Women with polycystic ovary syndrome who present with hyperandrogenemia, hyperinsulinemia, and insulin resistance appear to be at high risk of cardiovascular disease. Elevated levels of endothelin-1, a marker of vasculopathy, have been reported in insulin-resistant subjects with endothelial dysfunction. Male gender also seems to be an aggravating factor for cardiovascular disease. In this study we investigated endothelin-1 levels in women with polycystic ovary syndrome, and we evaluated the effect of an insulin sensitizer, metformin, on endothelin-1 levels. Plasma endothelin-1 levels were measured in 23 obese (mean age, 24.3 ± 4.6 yr; body mass index, 35 ± 5.6 kg/m2) and 20 nonobese women with polycystic ovary syndrome (24.1 ± 3.6 yr; body mass index, 21.8 ± 2.5 kg/m2) as well as in 7 obese and 10 nonobese healthy, normal cycling, age-matched women. Additionally, endothelin-1 levels were evaluated in a sub-group of women with polycystic ovary syndrome (10 obese and 10 nonobese) 6 months postmetformin administration (1700 mg daily). Our results showed that obese and nonobese women with polycystic ovary syndrome had higher levels of endothelin-1 compared with the controls [obese, 2.52 ± 1.87 vs. 0.44 ± 0.23 pmol/liter (by analysis of covariance, P &lt; 0.02); nonobese, 1.95 ± 1.6 vs. 0.43 ± 0,65 pmol/liter (P &lt; 0.009)]. All of the participating women with polycystic ovary syndrome (n = 43) when compared with the total group of controls (n = 17) demonstrated hyperinsulinemia (polycystic ovary syndrome, 24.5 ± 19.6; controls, 11.2 ± 3.4 U/liter; P &lt; 0.03), lower glucose utilization (M40) during the hyperinsulinemic euglycemic clamps (3.4 ± 2.4 vs. 5.6 ± 1.75 mg/kg·min; P &lt; 0.045, by one-tailed test), and higher levels of endothelin-1 (polycystic ovary syndrome, 2.52 ± 1.87; controls, 0.44 ± 0.23 pmol/liter; P &lt; 0.02, analysis of covariance covariate for body mass index). A positive correlation of endothelin-1 with free T levels was also shown (r = 0.4, P = 0.002) as well as a negative correlation of endothelin-1 with glucose utilization (r = -0.3; P = 0.033) in the total studied population. Finally, after metformin therapy, endothelin-1 levels were significantly reduced in obese (endothelin-1 before, 3.25 ± 2.2; endothelin-1 after, 1.1 ± 0.9 pmol/liter; P &lt; 0.003) and nonobese (endothelin-1 before, 2.7 ± 2; endothelin-1 after, 0.7 ± 0.4 pmol/liter; P &lt; 0.01) women with polycystic ovary syndrome, with no change in body mass index. Moreover, after metformin therapy, hyperandrogenemia and hyperinsulinemia were normalized, and glucose utilization improved [obese before: total T, 0.9 ± 0.15 ng/ml; fasting insulin, 22.2 ± 12.1 U/liter; glucose utilization, 2.15 ± 0.5 mg/kg·min; obese after: total T, 0.5 ± 0.2 ng/ml; fasting insulin, 11.6 ± 6 U/liter; glucose utilization, 4.7 ± 1.4 mg/kg·min 9P &lt; 0.003, P &lt; 0.006, and P &lt; 0.002, respectively); nonobese before: total T, 1 ± 0.5 ng/ml; fasting insulin, 15.5 ± 7.6 U/liter; glucose utilization, 3.4 ± 0.7 mg/kg·min; nonobese after: total T, 0.8 ± 0.5 ng/ml; fasting insulin, 9 ± 3.8 U/liter; glucose utilization, 6 ± 1.7 mg/kg·min (P &lt; 0.04, P &lt; 0.02, and P &lt; 0.0008, respectively)]. In conclusion, our data clearly demonstrate that women with polycystic ovary syndrome, obese and nonobese, have elevated endothelin-1 levels compared with the age-matched control group. In addition, 6 months of metformin therapy reduces endothelin-1 levels and improves their hormonal and metabolic profile
Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients
Background: Cutaneous lesions in myelodysplastic syndrome (MDS) may be specific or not and may reveal bone marrow transformation. Our purpose was to investigate in a cohort of 84 MDS patients the correlation of cutaneous findings with immunologic parameters and prognostic features of MDS in order to clarify their potential clinical significance. Materials and methods: We studied a cohort of 84 newly diagnosed MDS patients in order to assess the cutaneous findings present at the time of diagnosis and during 1 to 3.years of follow-up. We described the clinical variety of cutaneous findings ascertained by histology. We also looked for any association between the group of MDS patients with skin manifestations and MDS subtype, immunologic and prognostic features highlighting transformation to acute leukaemia. Results: Twenty-one patients presented cutaneous manifestations: 1 patient developed leukaemia cutis, 6 patients photosensitivity not associated with autoimmune disease, 3 prurigo nodularis, 2 Sweet's syndrome, 6 leucocytoclastic vasculitis, 2 ecchymoses and purpura associated with preexisting relapsing polychondritis, 1 patient subcutaneous nodules associated with Wegener's granulomatosis and 1 patient with malar rash and oral ulcers associated with preexisting systemic lupus erythematosus. Adjusted for age and gender, the presence of skin findings constitutes a significant predictor of the high-risk MDS subgroup (odds ratio, 3.59; 95% confidence interval, 1.18-10.92). Hypergammaglobulinemia was significantly higher in the MDS subgroup with skin manifestations (P = 0.03). Conclusion: Most MDS patients with cutaneous manifestations belong to the high-risk MDS subgroup and present hypergammaglobulinemia. Early biopsy of skin lesions in myelodysplasia is indicated. © 2007 The Authors Journal compilation © 2007 European Academy of Dermatology and Venereology
Giant adrenal myelolipoma, a rare urological issue with increasing incidence: a case report
INTRODUCTION: Adrenal myelolipomas are relatively rare, non-functioning benign tumours composed of mature fatty and active hematopoietic elements. They can be asymptomatic, even if their size is massive. Diagnosis is relatively simple using ultrasound, computed tomography and magnetic resonance imaging. Surgical resection through an extraperitoneal approach is advocated in cases of symptomatic or large myelolipomas exceeding 5-cm in diameter. Their low incidence seems to be increasing from 0.2% to 10% during the last decade. CASE PRESENTATION: We present a case of a giant adrenal myelolipoma in a 68-year-old Caucasian male, who was presented with left lumbar pain. Renal ultrasound, CT and MRI demonstrated a well demarcated mass, with a maximum diameter of 10-cm. The differential diagnosis comprised the adrenal myelolipoma, the retroperitoneal liposarcoma and the renal angiomyolipoma. Thus, the patient was subjected to a left adrenalectomy. CONCLUSION: Multiple theories have been proposed for the increasing frequency and natural course of the adrenal myelolipoma, with chronic adrenal stimulation and the contemporary stressful lifestyle to be the most appealing. Surgical treatment is advocated through an extraperitoneal approach because of the quicker recovery of the patient and the smaller postoperative complication rate
- …